123 related articles for article (PubMed ID: 38877512)
1. Higher prevalence of harbouring BCR::ABL1 in first-degree relatives of chronic myeloid leukaemia (CML) patients compared to normal population.
Kuan JW; Su AT; Sim SP; Tay SP
BMC Cancer; 2024 Jun; 24(1):734. PubMed ID: 38877512
[TBL] [Abstract][Full Text] [Related]
2.
Meza-Espinoza JP; Vásquez-Jiménez EA; Barajas-Torres RL; Magaña-Torres MT; González-García JR
Ann Clin Lab Sci; 2019 Nov; 49(6):703-709. PubMed ID: 31882420
[No Abstract] [Full Text] [Related]
3. Systematic Review of Normal Subjects Harbouring BCR-ABL1 Fusion Gene.
Kuan JW; Su AT; Leong CF; Osato M; Sashida G
Acta Haematol; 2020; 143(2):96-111. PubMed ID: 31401626
[TBL] [Abstract][Full Text] [Related]
4. Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network.
Schäfer V; White HE; Gerrard G; Möbius S; Saussele S; Franke GN; Mahon FX; Talmaci R; Colomer D; Soverini S; Machova Polakova K; Cross NCP; Hochhaus A; Ernst T
J Cancer Res Clin Oncol; 2021 Oct; 147(10):3081-3089. PubMed ID: 33677711
[TBL] [Abstract][Full Text] [Related]
5. Clinical and laboratory relevance of JAK2 V617F and BCR-ABL co-existence in Philadelphia positive CML patients.
Ahmad N; Qayum S; Jameel A; Ali A; Siraj S; Ali J; Yousafzai YM
Pak J Pharm Sci; 2021 Nov; 34(6(Supplementary)):2289-2295. PubMed ID: 35039265
[TBL] [Abstract][Full Text] [Related]
6. Genomic amplification of BCR-ABL1 fusion gene and its impact on the disease progression mechanism in patients with chronic myelogenous leukemia.
Chandran RK; Geetha N; Sakthivel KM; Aswathy CG; Gopinath P; Raj TVA; Priya G; Nair JKKM; Sreedharan H
Gene; 2019 Feb; 686():85-91. PubMed ID: 30399426
[TBL] [Abstract][Full Text] [Related]
7. Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCR-ABL1 fusion.
McCarron SL; Langabeer SE; Bolger K; Haslam K; Crampe M; Kelly J; Morrell R
Med Oncol; 2015 Feb; 32(2):452. PubMed ID: 25579165
[TBL] [Abstract][Full Text] [Related]
8. Comparison of molecular responses based on BCR-ABL1% (IS) results from an in-house TaqMan-based qPCR versus Xpert(®) assay in CML patients on tyrosine kinase inhibitor therapy.
Boeckx N; Laer CV; Roover JD; Wilmsen B; Bruyninckx K; Pauwels S
Acta Clin Belg; 2015 Aug; 70(4):237-43. PubMed ID: 26166681
[TBL] [Abstract][Full Text] [Related]
9. Detection of
Uzoma IC; Taiwo IA; Nna EO; Durosinmi MA; Ukaejiofo EO
Niger J Clin Pract; 2019 Jan; 22(1):51-55. PubMed ID: 30666020
[TBL] [Abstract][Full Text] [Related]
10. FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertions.
May PC; Reid AG; Robinson ME; Khorashad JS; Milojkovic D; Claudiani S; ; Willis F; Apperley JF; Innes AJ
BMC Med Genomics; 2023 Jul; 16(1):172. PubMed ID: 37496024
[TBL] [Abstract][Full Text] [Related]
11. The Clinical Significance of BCR-ABL1 Mutations in Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation.
Tachibana T; Kondo T; Uchida N; Doki N; Takada S; Takahashi S; Yano S; Mori T; Kohno A; Kimura T; Fukuda T; Atsuta Y; Nagamura-Inoue T;
Transplant Cell Ther; 2022 Jun; 28(6):321.e1-321.e8. PubMed ID: 35296447
[TBL] [Abstract][Full Text] [Related]
12. A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
Kitamura H; Tabe Y; Ai T; Tsuchiya K; Yuri M; Misawa S; Horii T; Kawaguchi A; Ohsaka A; Kimura S
PLoS One; 2019; 14(3):e0207170. PubMed ID: 30835732
[TBL] [Abstract][Full Text] [Related]
13. Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study.
Kizilors A; Crisà E; Lea N; Passera R; Mian S; Anwar J; Best S; Nicolini FE; Ireland R; Aldouri M; Pocock C; Corbett T; Gale R; Bart-Smith E; Weston-Smith S; Wykes C; Kulasekararaj A; Jackson S; Harrington P; McLornan D; Raj K; Pagliuca A; Mufti GJ; de Lavallade H
Lancet Haematol; 2019 May; 6(5):e276-e284. PubMed ID: 31036317
[TBL] [Abstract][Full Text] [Related]
14. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.
Iriyama N; Fujisawa S; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
Am J Hematol; 2015 Apr; 90(4):282-7. PubMed ID: 25530131
[TBL] [Abstract][Full Text] [Related]
15. Comparison of BCR-ABL1 quantification in peripheral blood and bone marrow using an International Scale-standardized assay for assessment of deep molecular response in chronic myeloid leukemia.
Greiner G; Ratzinger F; Gurbisz M; Witzeneder N; Taghizadeh H; Mustafa SGK; Mitterbauer-Hohendanner G; Esterbauer H; Mannhalter C; Sperr WR; Valent P; Hoermann G
Clin Chem Lab Med; 2020 Jul; 58(8):1214-1222. PubMed ID: 32084002
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia.
Zhang Z; Chen Z; Jiang M; Liu S; Guo Y; Wan L; Li F
BMC Cancer; 2019 Oct; 19(1):935. PubMed ID: 31594548
[TBL] [Abstract][Full Text] [Related]
17. Comparison of
DE Oliveira Sales L; Mesquita FP; DE Sousa Portilho AJ; DE Moraes Filho MO; DE Moraes MEA; Montenegro RC; Moreira-Nunes CA
In Vivo; 2019; 33(4):1119-1124. PubMed ID: 31280200
[TBL] [Abstract][Full Text] [Related]
18. Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.
Akram AM; Iqbal Z; Akhtar T; Khalid AM; Sabar MF; Qazi MH; Aziz Z; Sajid N; Aleem A; Rasool M; Asif M; Aloraibi S; Aljamaan K; Iqbal M
Cancer Biol Ther; 2017 Apr; 18(4):214-221. PubMed ID: 28278078
[TBL] [Abstract][Full Text] [Related]
19. Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with
Boucher L; Sorel N; Desterke C; Chollet M; Rozalska L; Gallego Hernanz MP; Cayssials E; Raimbault A; Bennaceur-Griscelli A; Turhan AG; Chomel JC
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895120
[TBL] [Abstract][Full Text] [Related]
20. BCR-ABL1 p210 screening for chronic myeloid leukemia in patients with peripheral blood cytoses.
Fenu E; O'Neill SS; Insuasti-Beltran G
Int J Lab Hematol; 2021 Dec; 43(6):1458-1464. PubMed ID: 34185393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
